Foundation Medicine, Inc.  

Our comprehensive genomic profiling tests provide information about clinically relevant biomarkers and genomic alterations to help match patients to approved targeted therapies, immunotherapies, and clinical trial options—giving physicians and patients powerful actionable insights for navigating cancer care.... More Info Less Info

As a leader in companion diagnostic (CDx) approvals, we are your ideal partner to help make your next breakthrough a standard of care.

Discovery & Translational Research
Our proven portfolio of high-quality comprehensive tests and our regulatory-ready dataset can accelerate clinical trial enrollment, inform trial design, or create new insights from your banked samples to discover biomarkers, identify resistance, or determine which patients could benefit from your therapy.

Clinical Development & CDx
Our FoundationOne®CDx and FoundationOne®Liquid CDx tests have 60% of all CDx approvals for NGS testing in the United States and Japan – the most of any diagnostic company² – and we have capabilities to develop our portfolio for the upcoming European Union In Vitro Diagnostics Regulation (EU IVDR).

Access & Commercialization
We provide broad access to precision medicine around the world, with our tests available in more than 100 countries, and offer flexible solutions to accelerate your commercial launch, such as our alert service to provide timely, de-identified alerts on biomarker populations to support marketing and sales effectiveness.... More Info Less Info

FoundationOne Tracker is a personalized, tissue-informed ctDNA monitoring test that provides objective insights to help you understand response to treatment for patients with advanced cancer, across all solid tumors.

Designed to be used in a series, FoundationOne Tracker uses a baseline derived from FoundationOne®CDx to provide tissue-informed ctDNA results without the need for an additional tissue test*.

Subsequent customized FoundationOne Tracker tests, powered by Natera’s Signatera^TM technology, are then performed, using only a simple blood sample at each timepoint to monitor changes to ctDNA levels.

Patient Access to FoundationOne Tracker:

• Covered by Medicare for monitoring of response to immune-checkpoint inhibitor (ICI) therapy for patients with all solid tumors.
• No out-of-pocket costs for Qualifying Original Medicare beneficiaries.

*Patients who have had FoundationOne CDx test results reported August 20, 2019, or later, do not require an additional tissue test to initiate FoundationOne Tracker ctDNA monitoring.

... More Info Less Info